august 24 2025 glp-1 UCI MIND | 💊 Novo Nordisk today announced disappointing results for their two clinical trials, EVOKE and EVOKE+, of their agonist semaglutide The Impact of GLP-1 on

Themes continuing from 2025 into 2026 As the obesity market moves into its acceleration phase, several trends that gained traction in 2025 will continue to influence strategies and market dynamics in 2026: As the obesity market evolves, there is a growing recognition that use of obesity medications to maintain weight will be critical for many people

What is evidence-based

Microglia Type of glial cell located throughout the brain and spinal cord that functions as a resident macrophage and is the first and main form of active immune defence in the central nervous system

[13] Important limitations in the current evidence base include: Most studies measure acute GLP-1 responses to single meals rather than long-term effects Sample sizes are often small, and study populations vary widely The magnitude of GLP-1 increase from dietary interventions is substantially smaller than that achieved with pharmaceutical GLP-1 agonists Individual responses vary considerably based on genetics, baseline metabolic health, and gut microbiome composition From a safety perspective , natural approaches to supporting GLP-1 production through whole foods and lifestyle modifications are generally considered safe for most individuals

Interleukin-1 (IL-1) is a mediator of immunity produced by monocytes and macrophages during infection and is essential to the host response against pathogens [32, 33]

Flow Wellness recommends using fresh medication within the recommended timeframe to help maximize the benefits of your weight loss program